AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +65

AbbVie stock nears its record high after a quarterly beat

Earnings report AI-generated analysis

📈 AbbVie stock reached USD 265.07 on September 24, 2026, trading just 1.60% below its 52-week high of USD 269.39.

💰 The company reported Q2 2026 EPS of USD 3.65, beating the consensus estimate of USD 3.61 by USD 0.04.

📊 Revenue grew 10.2% year over year to reach USD 16.99 billion, exceeding the USD 16.80 billion consensus.

🔄 AbbVie is successfully replacing Humira-era revenue with newer growth products while preserving earnings momentum.

🎯 Analysts maintain a Moderate Buy consensus with an average price target of USD 276.64, implying 4.36% upside.

📅 HSBC raised its price target from USD 300 to USD 315 and maintained a Buy rating on the stock.

🔮 AbbVie set Q3 2026 EPS guidance between USD 3.840 and USD 3.880 for future investor comparison.

📉 Daily trading volume was 3,429,067 shares with a session range of USD 263.09 to USD 267.41.

Bullish Signals
  • AbbVie stock reached USD 265.07 on September 24, 2026, trading just 1.60% below its 52-week high of USD 269.39.
  • The company reported Q2 2026 EPS of USD 3.65, beating the consensus estimate of USD 3.61 by USD 0.04.
  • Revenue grew 10.2% year over year to reach USD 16.99 billion, exceeding the USD 16.80 billion consensus.
  • Analysts maintain a Moderate Buy consensus with an average price target of USD 276.64, implying 4.36% upside from current levels.
  • HSBC raised its price target from USD 300 to USD 315 and maintained a Buy rating on the stock.
Full Analysis
AbbVie Inc. shares approached a record high on September 24, 2026, trading at USD 265.07 after the company reported strong second-quarter financial results. The quarterly earnings per share (EPS) beat analyst consensus estimates by USD 0.04, reaching USD 3.65 against an expected USD 3.61. This positive performance contributed to a year-over-year revenue increase of 10.2%, with total revenue climbing to USD 16.99 billion compared to the prior year. MarketBeat data highlights that AbbVie is successfully navigating its transition from Humira-era revenue by leveraging newer growth products while maintaining robust quarterly earnings momentum. The stock currently trades just 1.60% below its 52-week high of USD 269.39, reflecting investor confidence in the company's valuation and recent operational execution. Analyst consensus remains Moderate Buy with an average price target of USD 276.64, suggesting potential upside from current levels. Looking ahead to the third quarter, AbbVie has provided EPS guidance ranging between USD 3.840 and USD 3.880 for investors to track against upcoming results. The company's market capitalization stands at approximately USD 468 billion as of late September 2026. While analyst price targets vary, with HSBC raising its target to USD 315, the overall sentiment remains positive driven by solid financial beats and strategic product transitions.